Disease Progression

Subscribe to Selected New Research on Disease Progression

7910 relevant articles (481 outcomes, 1003 trials/studies) found for this Disease

Description: The worsening of a disease over time. This concept is most often used for chronic and incurable diseases where the stage of the disease is an important determinant of therapy and prognosis.

Also Known As:

Disease Progressions; Progression, Disease; Progressions, Disease

Relationship Network

Disease Context: Research Results

Signs and Symptoms Pathological Conditions

Pathologic Processes: 2211

Disease Attributes

Disease Progression: 7910

Related Diseases

1.	Neoplasms (Cancer)
2.	Infection
3.	Breast Neoplasms (Breast Cancer)
4.	Neoplasm Metastasis (Metastasis)
5.	Colorectal Neoplasms (Colorectal Cancer)

Experts

1.	Rouzioux, Christine: 6 articles (08/2008 - 04/2002)
2.	Kumar, Anil: 6 articles (08/2007 - 01/2006)
3.	Sterling, Timothy R: 5 articles (10/2007 - 03/2003)
4.	Noel, Richard J: 5 articles (08/2007 - 03/2006)
5.	Meyer, Laurence: 4 articles (08/2008 - 04/2002)
6.	Yu, Herbert: 4 articles (03/2008 - 02/2006)
7.	Miyake, Hideaki: 4 articles (09/2005 - 01/2002)
8.	Hara, Isao: 4 articles (09/2005 - 01/2002)
9.	Detels, R: 4 articles (04/2002 - 12/2000)
10.	Kolb, H: 3 articles (07/2008 - 01/2002)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Disease Progression:

1.	Biological Markers (Surrogate Marker)IBA 01/01/1991 - "These activities generate stabilization or improvement in three important surrogate markers of HIV disease progression" 12/01/1999 - "Future therapeutic modalities will also rely on more accurate clinical markers, such as improved magnetic resonance imaging techniques or specific immune markers to follow the disease progression" 04/01/2008 - "Potential clinical applications of biomarkers are found in improved diagnosis, monitoring of disease progression and assessment of therapeutic correction" 08/01/2004 - "As well as disclosing new therapeutic targets and preclinical and clinical data for drugs in development, several presentations discussed the development of surrogate markers and imaging techniques to monitor disease progression and therapeutic efficacy." 03/01/1993 - "We propose that serial quantitative measurement of saccade performance is a useful clinical marker of the rate of disease progression against which the efficacy of treatments may be tested." Order ALL the reference details at left...
2.	Paclitaxel (Taxol)FDA LinkGeneric 07/05/2000 - "CONCLUSION: The addition of paclitaxel to best supportive care significantly improved survival and time to disease progression compared with best supportive care in patients with advanced NSCLC and may improve some aspects of QOL." 08/01/1997 - "In the first 20 evaluable patients accrued (cohort A), myelosuppression was tolerable, but cumulative peripheral sensory neuropathy proved dose limiting: grade > or = 1 in 15 (75%) patients and grade 3 in six (30%), generally occurring at paclitaxel doses > or = 215 mg/m2 and obligating at least three patients to be removed from study despite absence of disease progression" 12/01/1996 - "Cumulative peripheral sensory neuropathy grade > or = 1 in 15 (75%) patients and grade 3 in six (30%), however, generally occurring at paclitaxel doses greater than 215 mg/m2, obligated removal from study of at least three patients, despite the absence of disease progression, and proved to be dose-limiting" 01/29/2008 - "twice daily on days 1-14 and paclitaxel 175 mg m(-2) i.v. on day 1 every 3 weeks until disease progression or unacceptable toxicities" 11/01/2007 - "Patients with paclitaxel t(C > 0.05) > 61.4 h (mean value) had a longer time to disease progression compared with patients with paclitaxel t(C > 0.05) < 61.4 h (89.0 versus 61.9 weeks; P = 0.05)" Order ALL the reference details at left...
3.	gemcitabine FDA Link 02/01/1999 - "RESULTS: Six of 31 assessable patients (19%) responded favorably to gemcitabine, 11 patients (35%) displayed no change, and 14 patients (45%) had disease progression" 12/01/2004 - "Randomized phase III trials with gemcitabine have yielded response rates that have translated into time to disease progression and survival benefits" 02/01/2007 - "METHODS: The records of 74 patients who were treated with gemcitabine (GEM) and followed up until disease progression were reviewed retrospectively" 09/01/2006 - "The response rate, time to disease progression and overall survival rates of this regimen are comparable to other standard therapies for MBC, as well as other gemcitabine combinations." 08/01/2005 - "Following the induction, patients without disease progression received gemcitabine administered twice weekly (40 mg/m2/day) for 5 weeks concurrent with upper abdominal radiation (50.4 Gy over 5.5 weeks)" Order ALL the reference details at left...
4.	Cisplatin (Platino)FDA LinkGeneric 01/01/1987 - "These findings provide reasons to study both treatment with cisplatin before disease progression reduces the number of favorable characteristics and systematic second attempts at debulking surgery." 07/01/2004 - "In the other 4 dogs cisplatin was not administered as prescribed because the dogs were withdrawn from treatment due to disease progression or radiation effects" 05/01/2001 - "Patients who do poorly despite ABMT have a mediastinal primary site, true cisplatin-refractory disease, disease progression prior to ABMT, and/or markedly elevated betaHCG at ABMT" 09/15/1993 - "Among the 24 MNSGCT, 10 were treated before 1980 without cisplatin and all but 1 died of disease progression" 01/01/1992 - "cisplatin administration) could be administered, the treatment principally being stopped because of disease progression or catheter failure" Order ALL the reference details at left...
5.	InterferonsIBA 02/01/2002 - "Disease improved in 14.6 and 1.6% of treated and untreated patients, respectively (P=0.015): interferon slowed disease progression (P<0.001)" 01/01/2001 - "REVIEWER'S CONCLUSIONS: The efficacy of interferon on exacerbations and disease progression in patients with relapsing remitting MS was modest after one and two years of treatment" 06/19/2008 - "In the present study, we assessed whether Gag-specific interferon (IFN)-gamma secreting responses correlate with the rate of disease progression as defined by the annual rate of CD4 decline" 02/01/2005 - "Nevertheless, recent studies have shown that histological features other than stage may have predictive value for disease progression and therapeutic response to interferon-based regimens" 01/01/2002 - "The role of axonal degeneration in the disease progression and data of the last trial of beta-interferons in secondary progressive MS are also discussed." Order ALL the reference details at left...
6.	imatinib (Gleevec)FDA Link 01/01/2006 - "While imatinib is highly effective therapy, with improving prospects over time for sustained remission and potential to severely limit or eliminate disease progression and transformation, a minority of patients either fail or respond suboptimally to imatinib; as well, disease eradication may not be possible with imatinib" 01/01/2008 - "CONCLUSION: This report supports the view that imatinib is a safe and effective drug in controlling disease progression in advanced metastatic GIST and plays an important role in improving the patient's quality of life." 03/01/2003 - "INTERPRETATION AND CONCLUSIONS: Based on this relatively small series of patients, we conclude that acquisition of clonal evolution increases the risk of subsequent disease progression also in CML patients in complete hematologic remission on imatinib." 03/01/2003 - "Therefore, to investigate whether CE as an isolated event increases the risk of disease progression during imatinib treatment, we compared the outcome of patients with CML in chronic phase (CML-CP) who developed CE whilst in complete hematologic remission with the outcome of comparable patients in complete hematologic remission who showed no evidence of CE" 03/01/2004 - "Earlier intervention played a role in preventing disease progression but this effect was not translated into better survival, which could have been overcome by imatinib mesylate, which induced MR and cytogenetic remission in nonresponders without toxicity." Order ALL the reference details at left...
7.	AntibodiesIBA 02/20/2004 - "The known structure of the fragments permits the generation of neo-epitope antibodies to the cleavage site, which can be used to detect ongoing cartilage degradation in patients with arthritic disease, an important adjunct in monitoring disease progression, active disease, and efficacy of treatment." 04/01/1999 - "Strong antibody responses are often seen in human immunodeficiency virus type 1 (HIV-1) carriers, but it is not known whether these antibodies are effective in the inhibition of disease progression" 06/01/2008 - "Since neutralizing antibodies (NAbs) can reduce the clinical efficacy of IFNbeta in patients with MS, clinicians should consider the possible development of NAbs in patients demonstrating disease progression while receiving IFNbeta treatment" 02/01/1989 - "These results argue against a role for antibodies to this LAV-1/HTLV-IIIB neutralization domain in protection against disease progression." 12/01/2004 - "Results of these studies demonstrated correlation between presence of anti-NTM antibodies in sera of HIV patients and disease progression measured by the CD4(+) cell count" Order ALL the reference details at left...
8.	trastuzumab (Herceptin)FDA Link 10/01/2004 - "The benefits noted with trastuzumab-containing regimens were documented in clinical trials where trastuzumab was given until disease progression" 09/01/2004 - "MATERIALS AND METHODS: Eighteen patients with HRPC were recruited for this phase II trial in which they received trastuzumab for 12 weeks or until disease progression or unacceptable toxicity was documented" 04/01/2004 - "We conducted a retrospective case review study of women with HER2-positive MBC who continued to receive trastuzumab beyond disease progression" 03/15/2004 - "PATIENTS AND METHODS: A total of 247 patients with documented disease progression received weekly intravenous trastuzumab in the extension study" 03/15/2004 - "We conducted an extension study to this trial to obtain additional safety information and to provide trastuzumab following disease progression" Order ALL the reference details at left...
9.	DNA (Deoxyribonucleic Acid)IBA 10/01/2000 - "All patients who responded to therapy demonstrated a significant reduction of plasma EBV DNA to low or undetectable levels, whereas in two patients with ineffective therapy, disease progression was associated with a rapid increase in plasma EBV DNA levels" 03/01/2001 - "CONCLUSION: Although the data for each individual measurement demonstrates overlap between patients with AD and control subjects, the ratio of 8-OHG intact in DNA to free 8-OHG demonstrates a delineation between patients with AD and control 8-OHG subjects and may be useful as a marker of disease progression or the efficacy of therapeutic antioxidant intervention." 04/01/2005 - "Future directions include validation of methods that reduce these inconsistencies by in vivo detection of abnormalities and by objective diagnostic markers besides grades of dysplasia, such DNA content analysis and molecular markers, and improved understanding of the disease progression" 02/01/2008 - "Recent studies report an association between HIV-1 DNA levels, disease progression, and treatment outcome" 11/01/2007 - "This article reviews results from the REVEAL-HBV study, which found that hepatitis B virus DNA across a biologic gradient is very strongly predictive of the risk of disease progression and remains a strong predictor of risk after accounting for other important factors." Order ALL the reference details at left...
10.	docetaxel (Taxotere)FDA Link 06/01/2008 - "All patients had been treated with docetaxel and had disease progression within 6 months after completion of first-line treatment" 10/01/1998 - "Objective response rates range from 30 to 57% with docetaxel monotherapy in clinical trials in patients with advanced disease who had failed to respond to previous therapy, and the median time to disease progression ranges from 17 to 20 weeks" 04/01/2008 - "METHODS: A phase 3 clinical trial was conducted in patients with MBC who were treated with docetaxel either every 3 weeks or once weekly to determine and compare response rate and duration, time to disease progression, progression-free survival (PFS), overall survival (OS), and toxicity" 04/01/2008 - "At a median follow-up duration of 11.3 months for surviving patients (range 6.3-18.8 months), the median time to disease progression was 2.5 months (95% CI, 2.3-2.7) and the median overall survival time since the start of docetaxel monotherapy was 8.3 months (95% CI, 6.7-9.8)" 09/01/2007 - "Five patients had improvement of disease status during sequential docetaxel, and seven patients had disease progression" Order ALL the reference details at left...

Therapies and Procedures

1.	Drug Therapy (Chemotherapy) 05/01/1992 - "Given this response rate to radiation therapy and the difficulty of dissection and associated morbidity with the surgical excision of postchemotherapy residual masses, the best option at this time may be observation with salvage chemotherapy and/or radiation reserved for those with disease progression." 01/01/1999 - "Chemotherapy resistance was defined as relapse after initial chemotherapy (11 patients) or failure to achieve complete remission (partial response in 18 patients, stable disease in 1 patient, and disease progression in 5 patients)" 07/01/1993 - "Thirty patients (71%) achieved a complete remission (CR; 21 chemotherapy alone, 9 with additional surgery), 8 patients (19%) a partial remission (PR), and 4 patients had disease progression (10%)" 10/01/1991 - "A mean lead time of 99 days (range 14 to 255 days) was demonstrated between marker detection of disease progression and clinically apparent progressive disease in 12 out of 13 patients (92%) who relapsed after chemotherapy induced complete remission" 05/01/2005 - "RESULT: Of the thirteen patients who underwent surgery in combination with multiagent systemic chemotherapy, seven achieved complete remission (CR), five had partial remission (PR), and one died of disease progression" Order ALL the reference details at left...
2.	Immunotherapy 08/01/1992 - "At the present time, data remain limited, but three controlled studies have found statistically significant reductions in the rate of disease progression, and one has found a significant reduction in the mortality rate, with BCG immunotherapy" 03/01/1999 - "RESULTS: Four out of twelve patients achieved complete remission (CR), one patient had a partial remission (PR), three were stable and four had disease progression under radio therapy and chemo-immunotherapy" 01/01/1995 - "In contrast, intravesical bacillus Calmette-Guérin (BCG) immunotherapy is effective in high-grade tumours, provides long-term protection from tumour recurrence and reduces disease progression" 04/15/2004 - "The immunotherapy appears to prevent disease progression, although no protection against reinfection with LP-BM5 is generated" 02/01/2008 - "Forthcoming immunotherapy studies should soon show whether the prevention of Abeta deposition interrupts disease progression." Order ALL the reference details at left...
3.	Highly Active Antiretroviral Therapy (HAART) 08/01/2004 - "Monitoring the efficacy of highly active antiretroviral treatment (HAART) is crucial if disease progression and the emergence of viral mutants are to be avoided" 07/01/2001 - "Highly active antiretroviral therapy (HAART) has been shown to be highly effective in controlling HIV-related disease progression" 06/01/2007 - "The understanding of viral pathogenesis, the development of highly active antiretroviral therapy, and the ability to quantitate viral burden have led to significant reduction in disease progression and morbidity in HIV-infected children" 06/01/2006 - "HAART use in pregnancy provides significant benefits in delaying HIV disease progression and reducing the risk of mother-to-child-transmission, but may be counterproductive in terms of successful pregnancy outcome." 11/23/2001 - "Further longitudinal follow-up will be needed to better ascertain whether HAART initiated at > 200 x 10(6) CD4 lymphocytes/l is effective in slowing disease progression." Order ALL the reference details at left...
4.	Transplants (Transplant) 12/27/1996 - "Early complete hemodynamic evaluation before the onset of severe symptoms, followed by serial evaluations of disease progression and consultation with a transplant center, should result in earlier, more appropriate time of listing and improved survival" 02/01/2001 - "The use of this immunoablative conditioning regimen in auto-HSCT transplant was shown to be effective in controlling disease progression and could be a valuable strategy in reducing TRM." 08/01/2007 - "The primary trial endpoint was significant graft disease progression assessed angiographically" 09/01/2006 - "CONCLUSION: Our study suggests that antiviral treatment withdrawal carries the risk of severe disease progression in persistently viremic HCV-positive liver transplant patients." 12/01/2002 - "This is a particularly interesting finding given that the SDS gene has recently been mapped to the centromeric region of chromosome 7. Our studies indicate that i(7)(q10) is a relatively benign rearrangement and that it is not advisable to offer allogeneic transplants to SDS children with i(7)(q10) alone in the absence of other clinical signs of disease progression." Order ALL the reference details at left...
5.	Aftercare (After-Treatment) 01/01/2003 - "Time to disease progression or death after treatment with UFT/LV in one study appears to be shorter than after treatment with 5-FU/LV with the Mayo regimen, although it also had an improved adverse effect profile" 12/01/2006 - "Two groups of patients were selected: patients who experienced first-line treatment failure less than 60 days from treatment discontinuation (refractory group), and patients who responded to first-line treatment and experienced disease progression > or = 60 days after treatment discontinuation (sensitive group)" 05/01/2008 - "Probabilities regarding disease progression after treatment with the investigated drugs were extracted from two published clinical trials" 07/01/2007 - "The purpose of this review is to identify how CRP levels may be useful for monitoring the effect of therapy on halting disease progression and why monitoring CRP levels at baseline and after treatment should become a routine part of clinical practice." 04/01/2007 - "As greater knowledge is accumulated about gene therapy, correlations will be made between the level of gene expression from the therapeutic vector, the extent of correction after treatment, and the stage of disease progression when therapy is initiated." Order ALL the reference details at left...

Best Treatments:
Research Summary Report
on Disease Progression

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 481 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>